August 3, 2020 -- Neutrolis has developed a new class of COVID-19 therapy, a DNASEIL3 enzyme analog that has the potential to clear neutrophil extracellular traps (NETs) for severe cases of COVID-19.
The candidate, Ntr-441, is an engineered analog of a natural NET-destroying enzyme encoded by the DNASEIL3 gene. The analog was developed on the company's proprietary Chromatinase platform and is based on a naturally occurring enzyme that breaks down the extracellular chromatin that forms NETs.
Several independent researchers have confirmed that NETs are associated with the clinical severity of COVID-19. Moreover, the company recently published a study in the Lancet's EBioMedicine open-access journal that found NETs in the lungs of COVID-19 patients. The candidate is being developed in part with funding from the National Institutes of Health, and the company plans to pursue testing to evaluate whether Ntr-441 is effective for treating COVID-19.